Certified Diabetes Educator Practice Exam

Semaglutide, marketed as Ozempic, is recognized for its significant impact on weight loss among patients with type 2 diabetes. This GLP-1 receptor agonist enhances insulin secretion when blood sugar levels are elevated and suppresses the release of glucagon, thereby contributing to better glycemic control.

The notable aspect of Semaglutide, particularly in the context of weight loss, is that clinical studies have demonstrated its effectiveness in reducing body weight significantly in conjunction with a reduced-calorie diet and increased physical activity. Participants in these studies have experienced an average weight loss of around 15% or more, which is substantial compared to other medications in this class.

Additionally, Semaglutide affects appetite regulation in the brain, leading to decreased caloric intake and promoting a feeling of satiety. This mechanism sets it apart from other GLP-1 receptor agonists, as it has been explicitly studied and approved for weight management, making it a preferred choice for patients focusing on weight loss alongside diabetes management.

Therefore, its dual role in controlling blood glucose and fostering weight reduction is why Semaglutide holds a prominent position in discussions about GLP-1 receptor agonists and their benefits regarding weight loss.